[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100408057":3},{"organization":4,"armGroups":7,"interventions":21,"overallOfficials":10,"centralContacts":39,"locations":45,"responsibleParty":63,"collaborators":66,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":76,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":10,"studyType":83,"phases":10,"briefSummary":84,"conditions":85,"keywords":92,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Karolinska Institutet","OTHER",[8,17],{"label":9,"type":10,"description":11,"interventionNames":12},"ESVEA",null,"ESVEA (Excessive supraventricular ectopic activity): Participants with at least 30 supraventricular extra systole (SVES)\u002Fh or a supraventricular run of at least 20 beats.",[13,14,15,16],"Diagnostic Test: Holter recording","Diagnostic Test: Echocardiography (Echo)","Diagnostic Test: Blood sample","Diagnostic Test: 24 hour ambulatory blood pressure monitoring And Arteriograph",{"label":18,"type":10,"description":19,"interventionNames":20},"Non-ESVEA","Participants not meeting inclusion criteria",[13,14,15,16],[22,27,31,35],{"type":23,"name":24,"description":25,"armGroupLabels":26,"otherNames":10},"DIAGNOSTIC_TEST","Holter recording","Holter recording with Zenicor Flex ECG during 14 days.",[9,18],{"type":23,"name":28,"description":29,"armGroupLabels":30,"otherNames":10},"Echocardiography (Echo)","Echocardiography: Comprehensive transthoracic echocardiography with special focus on atrial dimension and function.",[9,18],{"type":23,"name":32,"description":33,"armGroupLabels":34,"otherNames":10},"Blood sample","Blood sample: 2 x 10 ml EDTA plasma sampled from venous blood at index and at 21 months. Troponin T, NTproBNP, Na, K, Creatinine. Sample for Biobank for future analysis.",[9,18],{"type":23,"name":36,"description":37,"armGroupLabels":38,"otherNames":10},"24 hour ambulatory blood pressure monitoring And Arteriograph","To assess artery stiffness.",[9,18],[40],{"name":41,"role":42,"phone":43,"phoneExt":10,"email":44},"Johan Engdahl","CONTACT","0046812358242","johan.engdahl@regionstockholm.se",[46],{"facility":47,"status":48,"city":49,"state":10,"zip":10,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Danderyd Hospital","RECRUITING","Stockholm","Sweden","SE",{"type":53,"coordinates":54},"Point",[55,56],18.06871,59.32938,{"lat":56,"lon":55},[59,60],{"name":41,"role":42,"phone":10,"phoneExt":10,"email":44},{"name":61,"role":42,"phone":10,"phoneExt":10,"email":62},"Mehrnoosh Hossein beky","mehr.hossein-beky@regionstockholm.se",{"type":64,"investigatorFullName":41,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","MD, Associate Professor",[67],{"name":47,"class":6},"100408057","excessive-supraventricular-activity-and-atrial-fibrillation-100408057",false,"NCT04593498","Excessive Supraventricular Activity and Atrial Fibrillation","Detection of Atrial Fibrillation in Patients With Excessive Supraventricular Activity","ESA-AF","Inclusion Criteria:\n\nPatients with at least 30 supraventricular extra systole (SVES)\u002Fh or a supraventricular run of at least 20 beats on a Holter recording.\n\nExclusion Criteria:\n\nAge \\\u003C 70 years, \\>89 years Atrial fibrillation \u002F flutter Lifelong treatment with oral anticoagulant Patients with implantable cardiac device Congestive heart failure (CHF) with Ejection fraction (EF) ≤ 30% Severe valvular heart disease",true,"ALL","70 Years","89 Years",{"count":81,"type":82},250,"ESTIMATED","OBSERVATIONAL","The aim of the proposed study is to determine if individuals with excessive supraventricular ectopic activity (ESVEA) on Holter recording should be subjected to prolonged screening with Event loop recorder in order to detect previously undiagnosed Atrial fibrillation \u002F flutter. Other biomarkers such as plasma biomarkers, high-end echocardiography and assessment of blood pressure and atrial stiffness will be studied and compared in ESVEA and control group as well as progression of atrial cardiomyopathy in ESVEA patients.",[86,87,88,89,90,91],"Atrial Fibrillation","Atrial Flutter","Supraventricular Beat, Premature","Premature Supraventricular Beats","Premature Atrial Complex","Extrasystole, Atrial",[93],"Excessive supraventricular ectopic activity","2024-03-05",{"date":96,"type":97},"2024-03-06","ACTUAL",{"date":99,"type":97},"2022-11-01",{"date":101,"type":82},"2028-02-15",{"name":5,"class":6},1]